Building Life

Founded in 2013, Arcturus is a leader in RNA medicines.

Placeholder

Arcturus Therapeutics

  • Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.READ MORE
  • Janssen Pharmaceuticals, Inc entered into a research collaboration and worldwide license agreement with Arcturus to develop and commercialize RNA-based drug products.Janssen Pharmaceuticals, Inc entered into a research collaboration and worldwide license agreement with Arcturus to develop and commercialize RNA-based drug products.READ MORE
  • Arbutus obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleomonomer Agent (UNA) from Arcturus.Arbutus obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleomonomer Agent (UNA) from Arcturus.

Proprietary Technologies

UNA and LUNAR™ Will Revolutionize RNA Medicines

TRANSPORTERS RECEPTORS ANTIBODIES ENZYMES TALEN GPCR’S HORMONES CHAPERONES CAR-T CRISPR
Trans-membrane Proteins Secreted Proteins Intracellular Proteins Engineered Antigens Engineered Nucleases
READ MORE

RNA Medicines

  • Antisense RNA
    Antisense RNA works by binding to messenger RNA (mRNA) and physically preventing the cell from translating the mRNA into protein. READ MORE
  • Gene Editing
    Human DNA has roughly 20 000 genes. Each gene contains the code needed to make one or more proteins. READ MORE
  • MircoRNA
    MicroRNA medicines can be used to treat complex diseases like cancer that are caused by many different malfunctioning proteins. READ MORE
  • mRNA
    Messenger RNA (mRNA) therapeutics can treat diseases caused by a lack of protein, or by defective proteins, such as Duchenne muscular dystrophy and cystic fibrosis. READ MORE
  • RNA
    RNA medicines can target any gene or protein in humans and so can be used to treat diseases that cannot be treated by conventional drugs such as small molecules and biologics. READ MORE
  • RNAi
    RNA interference (RNAi) is a natural mechanism used by the body to turn genes off without permanently changing DNA. READ MORE
  • siRNA
    Small interfering RNA (siRNA) medicines can treat viral infections like hepatitis B and diseases like Huntington’s disease that are caused by malfunctioning proteins. READ MORE

Pipeline

name

LUNAR-OTC

indication
OTC Deficiency
api
mUNA

INTERNAL mUNA PROGRAMS

RESEARCH

name

LUNAR-JNJ1

indication
Undisclosed
api
siUNA

PARTNERED PROGRAMS

PRECLINICAL

name

Arbutus, ARB-1467

indication
Hepatitis B
api
siUNA

LICENSED PROGRAMS

CLINICAL

News & Events

  • June 1, 2016

    Arcturus Therapeutics To Present At 2016 BIO International Convention in San Francisco

    • June 1 2016
    • 0
    read more
  • March 16, 2016

    Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology

    • March 16 2016
    • 0
    read more
  • January 6, 2016

    Arcturus Therapeutics Selected to Present at Biotech Showcase™ 2016

    • January 6 2016
    • 0
    read more
  • November 11, 2015

    International mRNA Health Conference

    • November 11 2015
    • 0
    read more
  • November 3, 2015

    Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board

    • November 3 2015
    • 0
    read more
  • October 29, 2015

    Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases

    • October 29 2015
    • 0
    read more
  • October 29, 2015

    Ultragenyx gives Arcturus rocket shot in potential $1.57B deal

    • October 29 2015
    • 0
    read more
  • October 11, 2015

    2015 Oligonucleotide Therapeutics Society

    • October 11 2015
    • 0
    read more
  • June 11, 2015

    Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications

    • June 11 2015
    • 0
    read more